Tissue Destruction and Healing in Celiac Disease
Key facts
- Where
- Chicago, Pasadena, and Rochester, United StatesSee the 3 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT05680012, who can take part
Where in United States
- The University Of ChicagoChicago, United StatesContact: Bana Jabri, MDTaking people
- California Institute of TechnologyPasadena, United StatesContact: Rustem Ismagilov, PhDNot yet recruiting
- Mayo ClinicRochester, United StatesContact: Joseph Murray, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University of Chicago
- Trial code
- NCT05680012
- Record updated
- 28 July 2026
- Original description
The purpose of this clinical study is to learn more about celiac disease pathogenesis and clinical symptoms. In particular, this study will examine the interactions between biological factors such as, intestinal epithelial cells, microbiota, immune system, genetics, and gluten and their effect on celiac disease clinical symptoms, and severity of tissue destruction and its ability to heal in individuals with celiac disease. Information collected in the study will help researchers to generate better resources to advance celiac disease patient care.Read full original descriptionShow less
The purpose of this clinical study is to learn more about celiac disease pathogenesis and clinical symptoms. In particular, this study will examine the interactions between biological factors such as, intestinal epithelial cells, microbiota, immune system, genetics, and gluten and their effect on celiac disease clinical symptoms, and severity of tissue destruction and its ability to heal in individuals with celiac disease. Information collected in the study will help researchers to generate better resources to advance celiac disease patient care.
Inclusion: Gluten challenge group:; Age 18 to 75 years old; Diagnosis of Celiac disease for at least 12 months by intestinal biopsy; Follow a strict gluten-free diet for at least the 12 consecutive months; Gluten de-challenge group:; Age 18 to 75 years old; Showing typical celiac disease symptoms; Not on a gluten-free diet; Control group:; Age 18 to 75 years old; Females who are not pregnant.
Exclusion: Gastrointestinal illness within the 4-week period prior to screening; Taking antibiotics, proton pump inhibitors, aspirin, or non-steroidal anti-inflammatory drugs; Prior gastrointestinal surgery; Diagnosis of any severe complication of celiac disease; Diagnosis of other chronic, active GI disease; Any clinically significant diseases; History of significant substance or alcohol abuse; Diagnosis of blood clotting disorders; Gluten de-challenge group:; History of chronic inflammatory gastrointestinal disease; History of lymphoproliferative disease; Uncontrolled blood clotting disorders; Any clinically significant diseases; History of significant substance or alcohol abuse; Control group:; Family history of celiac disease; Gluten challenge group:; Selective IgA deficiency; Severe reaction to gluten exposure; Pregnant or lactating; Known intestinal inflammation; Taking of antiplatelet agents or anticoagulants.